NYSE - Nasdaq Real Time Price USD
Novo Nordisk A/S (NVO)
64.37
-1.78
(-2.69%)
At close: May 16 at 4:00:02 PM EDT
66.16
+1.79
+(2.78%)
Pre-Market: 7:52:50 AM EDT
Research Analysis
Earnings Estimate
| Currency in DKK | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 7 | 8 |
| Avg. Estimate | 5.92 | 6.38 | 26.41 | 31.06 |
| Low Estimate | 5.78 | 6.16 | 25.51 | 29.12 |
| High Estimate | 6.18 | 6.5 | 27.93 | 33.6 |
| Year Ago EPS | 4.49 | 6.12 | 22.63 | 26.41 |
Revenue Estimate
| Currency in DKK | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 24 | 24 |
| Avg. Estimate | 77.83B | 83.26B | 336.43B | 388.04B |
| Low Estimate | 73.95B | 78.38B | 319.64B | 353.69B |
| High Estimate | 81.46B | 86.5B | 361.02B | 423.44B |
| Year Ago Sales | 68.06B | 71.31B | 290.4B | 336.43B |
| Sales Growth (year/est) | 14.35% | 16.76% | 15.85% | 15.34% |
Earnings History
| Currency in DKK | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | 4.91 | 5.92 | 6.11 | 6.07 |
| EPS Actual | 4.49 | 6.12 | 6.34 | 6.53 |
| Difference | -0.42 | 0.2 | 0.22 | 0.46 |
| Surprise % | -8.61% | 3.44% | 3.68% | 7.51% |
EPS Trend
| Currency in DKK | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 5.92 | 6.38 | 26.41 | 31.06 |
| 7 Days Ago | 5.98 | 6.56 | 26.29 | 31.4 |
| 30 Days Ago | 5.94 | 6.76 | 26.65 | 31.57 |
| 60 Days Ago | 6.68 | 7.05 | 27.34 | 33.3 |
| 90 Days Ago | 6.69 | 7.06 | 27.4 | 33.58 |
EPS Revisions
| Currency in DKK | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | 1 | 2 | 1 | 3 |
| Down Last 30 Days | 1 | 2 | 3 | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NVO | 31.75% | 4.21% | 16.72% | 17.58% |
| S&P 500 | 13.31% | 2.67% | 7.78% | 13.74% |
Upgrades & Downgrades
| Downgrade | BMO Capital: Outperform to Market Perform | 4/17/2025 |
| Upgrade | UBS: Sell to Buy | 1/8/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 12/23/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 11/6/2024 |
| Maintains | Citigroup: Buy to Buy | 10/22/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 10/17/2024 |
Related Tickers
LLY Eli Lilly and Company
757.39
+3.50%
PFE Pfizer Inc.
22.83
+1.02%
MRK Merck & Co., Inc.
76.06
+1.68%
ABBV AbbVie Inc.
184.02
+1.29%
JNJ Johnson & Johnson
151.33
+1.15%
BMY Bristol-Myers Squibb Company
46.75
+2.05%
AMGN Amgen Inc.
272.41
+1.15%
AZN AstraZeneca PLC
68.81
+1.25%
GILD Gilead Sciences, Inc.
102.50
+2.15%
NVS Novartis AG
109.59
+1.04%